Products & Innovation / Pipeline

Everything we’re building for CNS cancer.

CNSide®, our cerebrospinal fluid (CSF) assay, is commercially available and in clinical use across the U.S. The investigational radiotherapeutic REYOBIQ™ (rhenium Re 186 obisbemeda) is in three active ReSPECT™ trials. The data layer compounds behind both.

Our full pipeline at a glance.

Integrating precision diagnostics, targeted therapeutics, and data insights to improve outcomes for patients with central nervous system (CNS) cancers.

Diagnostic

CNSide®

CNSide®

In development Launching soon Commercial
Detection & Monitoring
Molecular Profiling
Targeted Biomarker Analysis
Detection & Monitoring

Stage: Commercial

Molecular Profiling

Stage: Commercial

Targeted Biomarker Analysis

Stage: Launching soon

Therapeutics

REYOBIQ™

REYOBIQ™

In development Phase 1 Phase 2 Phase 3 Launching soon Commercial
Recurrent Glioblastoma
Leptomeningeal Metastases
Pediatric Ependymoma & High-Grade Glioma
Recurrent Glioblastoma

Stage: Phase 2

Leptomeningeal Metastases

Stage: Phase 2

Pediatric Ependymoma & High-Grade Glioma

Stage: Phase 1

Data Insights
In development Launching soon Commercial
Clinical Intelligence Platform
Clinical Intelligence Platform

Stage: In development

Where the programs stand.

3

3 active ReSPECT™ trials, advancing REYOBIQ™ across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.

$24M

$24M in non-dilutive National Cancer Institute (NCI), Cancer Prevention and Research Institute of Texas (CPRIT), and Department of Defense (DoD) support behind the therapeutic program.

5

5 FDA designations. U.S. FDA has granted REYOBIQ™ five regulatory designations: Orphan Drug Designation for glioblastoma; Orphan Drug Designation for leptomeningeal metastases in breast cancer and lung cancer patients; and Fast Track Designation for leptomeningeal metastases and recurrent glioblastoma.

Innovative technologies that expand possibilities for CNS cancers.

The focus stays on the CNS. The underlying radiotherapeutic technology potential reaches further.